文献速递颈动脉与弓上血管

太平洋西北地区无症状患者颈动脉支架置入术卒中/死亡发生率升高与高风险患者选择相关

The elevated stroke and death rates among asymptomatic patients undergoing carotid stenting in the Pacific Northwest are associated with high-risk patient selection.
PubMed 文献 · J Vasc Surg · 2024-12-17

本研究回顾性分析了2016至2022年太平洋西北地区27个中心1154例无症状颈动脉狭窄患者的颈动脉支架置入术结局,总体卒中/死亡率为TCAR 2.5%、TF-CAS 3.0%。卒中/死亡率超过3%的中心均为高容量中心,且其治疗的患者更多具有高风险解剖和高风险生理(ASA 4或5级),狭窄程度>80%者较少。作者认为高卒中/死亡率似乎由选择狭窄<80%的高风险患者驱动。

要点

  • 无症状颈动脉狭窄支架置入术后30天内卒中/死亡复合发生率:TCAR 2.5%,TF-CAS 3.0%。
  • 卒中/死亡率>3%的中心均为容量排名前一半的中心。
  • 高卒中/死亡率中心治疗更多高风险解剖和高风险生理(ASA 4或5级)患者,狭窄>80%者较少。

核心结论

  • 太平洋西北地区颈动脉支架置入术的高卒中/死亡率似乎由选择狭窄<80%的高风险患者驱动。
  • 减少对生理风险极高(包括ASA 4级)及狭窄<80%的无症状患者行颈动脉血运重建的频率,可能有助于改善结局。

研究设计与样本

  • 回顾性综述,纳入2016至2022年太平洋西北地区血管质量倡议(VQI)中接受TCAR或TF-CAS的无症状患者,共1154例,来自27个中心。
  • 其中886例(76.8%)接受TCAR,268例(23.2%)接受TF-CAS。
  • 主要结局为指数住院后30天内卒中或死亡的复合终点;高卒中/死亡率定义为大于3%。

主要发现

  • 总体卒中/死亡率:TCAR为2.5%,TF-CAS为3.0%。
  • 卒中/死亡率>3%的中心(TCAR和TF-CAS均是)全部为容量排名前一半的中心。
  • TCAR患者中,高卒中/死亡率中心年血运重建量更高(12例/年 vs 7例/年,P = .03),治疗狭窄>80%者更少(42.1% vs 52.2%,P < .01),高风险解剖更多(42.3% vs 35.3%,P = .01),ASA 4或5级更多(25.5% vs 17.5%,P < .01)。
  • TF-CAS患者中,高卒中/死亡率中心高风险解剖更多(63.5% vs 48.6%,P = .03),ASA 4或5级更多(23.5% vs 10.4%,P < .01)。

关键数值与推荐

  • 当前指南推荐:无症状颈动脉狭窄患者当卒中/死亡发生率可低于3%时应予治疗。
  • 本研究将高卒中/死亡率定义为大于3%。
  • 高风险生理定义为美国麻醉医师协会(ASA)分级4或5级。

临床怎么用

  • 作者认为,减少对生理风险极高(包括ASA 4级)及狭窄<80%的无症状患者行颈动脉血运重建的频率,可能有助于改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Current guidelines recommend treatment of patients with asymptomatic carotid stenosis when stroke/death rates less than 3% can be achieved. However, in the Pacific Northwest region of the Vascular Quality Initiative, elevated stroke/death rates have been reported. This study aims to characterize regional and center-specific outcomes for transcarotid artery revascularization (TCAR) and transfemoral carotid artery stenting (TF-CAS) and investigate potential underlying drivers. METHODS: A retrospective review of asymptomatic patients undergoing TCAR and TF-CAS in the Vascular Quality Initiative for the Pacific Northwest region from 2016 to 2022 was performed. The primary outcome was the composite of stroke or death within 30 days of index hospitalization. Overall regional outcomes and center-specific outcomes were assessed. A high stroke/death rate was defined as greater than 3%. Demographics, comorbidities, and operative risk factors were then compared between centers with high and low stroke/death rates. RESULTS: A total of 1154 asymptomatic patients across 27 centers underwent carotid stenting in the Pacific Northwest from 2016 to 2022, of which 886 (76.8%) underwent TCAR and 268 (23.2%) underwent TF-CAS. The overall stroke/death rates were 2.5% and 3.0% for TCAR and TF-CAS, respectively. Among centers with stroke/death rates above 3%, for both TCAR and TF-CAS, all were in the top one-half of centers by volume. When patients undergoing TCAR were assessed, those treated at centers with high stroke/death rate underwent revascularization at higher volume centers (12 vs 7 cases per year; P = .03), which treated fewer patients with >80% stenosis (42.1% vs 52.2%; P < .01) and more patients with high-risk anatomy (42.3% vs 35.3%; P = .01), and high-risk physiology as defined by an American Society of Anesthesiologists (ASA) class of 4 or 5 (25.5% vs 17.5%; P < .01). Among patients undergoing TF-CAS, those treated at centers with a high stroke/death rate were more likely to have high-risk anatomy (63.5% vs 48.6%; P = .03), and high-risk physiology as defined by an ASA class of 4 or 5 (23.5% vs 10.4%; P < .01). CONCLUSIONS: High stroke/death rates in the Pacific Northwest appear to be driven by the selection of high-risk patients with less than 80% stenosis. Decreasing the frequency of carotid revascularization in asymptomatic patients with very high physiologic risk including those with ASA class 4 and those with less than 80% stenosis may offer the opportunity for improved outcomes.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ghosh R, Elizaga N, Murphy B, et al. The elevated stroke and death rates among asymptomatic patients undergoing carotid stenting in the Pacific Northwest are associated with high-risk patient selection. J Vasc Surg. 2024. PMID: 39701336. doi:10.1016/j.jvs.2024.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。